MEA Cancer Vaccines Market Report

MEA Cancer Vaccines Market Size

The Middle East & Africa Cancer Vaccines Market is projected to grow from USD 0.48 billion in 2025 to USD 0.56 billion in 2026 and reach USD 2.00 billion by 2034, registering a CAGR of 17.19% during the forecast period from 2026 to 2034.

The MEA (Middle East and Africa) Cancer Vaccines Market refers to the development, distribution, and administration of vaccines aimed at preventing or treating various types of cancers prevalent in the region. Unlike conventional vaccines that target infectious diseases, cancer vaccines are designed to either prevent virus-induced cancers or stimulate immune responses against malignant cells. The market has seen growing interest due to rising incidence rates of preventable cancers such as cervical cancer, liver cancer, and certain hematological malignancies linked to viral infections like Human Papillomavirus (HPV), Hepatitis B Virus (HBV), and Epstein-Barr Virus (EBV).

According to the World Health Organization (WHO), cervical cancer remains a major public health issue in Sub-Saharan Africa, where it is the leading cause of cancer-related deaths among women. In the Middle East, increasing awareness and government initiatives have led to the gradual integration of preventive oncology into national immunization programs.

As per the International Agency for Research on Cancer (IARC), several countries in North Africa have made progress in HPV vaccine adoption, particularly in Egypt and Morocco. These developments, coupled with international funding and regional collaborations, have positioned the MEA Cancer Vaccines Market on a growth trajectory, albeit unevenly across different sub-regions.

MARKET DRIVERS

Rising Prevalence of HPV-Related Cancers in Sub-Saharan Africa

One of the primary drivers of the MEA Cancer Vaccines Market is the high prevalence of Human Papillomavirus (HPV)-related cancers, particularly cervical cancer, in Sub-Saharan Africa.

According to the International Agency for Research on Cancer (IARC), approximately 70,000 new cases of cervical cancer were diagnosed annually in Sub-Saharan Africa between 2020 and 2023 , making it the most common cause of female cancer mortality in the region. This alarming trend has prompted increased efforts by governments and global health organizations to scale up HPV vaccination campaigns.

For instance, in Kenya, as per the Ministry of Health, over 90% of cervical cancer cases were linked to HPV infection , reinforcing the urgency for preventive interventions.

Also, according to the World Health Organization (WHO), in Nigeria, only a small share of women had access to regular cervical screening , highlighting the critical need for early prevention through vaccination. Gavi, the Vaccine Alliance, has supported HPV vaccine introductions in several African nations, including Malawi, Rwanda, and Ghana, contributing to improved coverage and awareness. These factors collectively underscore the growing demand for HPV-based cancer vaccines and their pivotal role in reducing the disease burden in the MEA region.

Increasing Government and Donor Support for Preventive Oncology Programs

Another key driver fueling the MEA Cancer Vaccines Market is the growing support from both national governments and international donor agencies in promoting preventive oncology through vaccination. Several African and Middle Eastern countries have initiated large-scale immunization programs backed by financial and technical assistance from organizations such as Gavi, UNICEF, and the Bill & Melinda Gates Foundation.

According to the Pan American Health Organization’s (PAHO) global vaccine equity reports, which also include data from MEA countries, Rwanda achieved high HPV vaccine coverage among adolescent girls by 2023, largely due to strong policy backing and donor collaboration. Similarly, in the United Arab Emirates, the Ministry of Health launched a nationwide HPV vaccination program in 2022 targeting schoolgirls, aligning with broader regional efforts to reduce cervical cancer incidence. The African Union’s Health Department further emphasized that eight out of ten newly introduced HPV vaccination programs in Africa between 2020 and 2023 received external funding , indicating sustained international commitment. These initiatives not only improve vaccine accessibility but also enhance public awareness and trust, thereby reinforcing long-term demand for cancer vaccines across the MEA region.

MARKET RESTRAINTS

Limited Healthcare Infrastructure and Vaccine Distribution Challenges

A significant restraint affecting the MEA Cancer Vaccines Market is the inadequate healthcare infrastructure, particularly in rural and conflict-affected regions of Sub-Saharan Africa and parts of the Middle East. Many health facilities lack essential cold chain storage, trained personnel, and reliable transportation networks required for effective vaccine delivery.

According to the World Health Organization (WHO), less share of health centers in rural areas of Ethiopia, South Sudan, and Chad had functional refrigeration systems for vaccine storage in 2023 , compared to that in urban settings. This disparity results in substantial vaccine wastage and limited outreach to vulnerable populations. In Yemen, ongoing political instability and disrupted supply chains have severely impacted immunization coverage. In addition, logistical inefficiencies during mass immunization campaigns have led to inconsistent coverage rates across the region. These systemic challenges continue to hinder the scalability and effectiveness of cancer vaccination programs across the MEA region.

Low Public Awareness and Vaccine Hesitancy

Another critical challenge impeding the growth of the MEA Cancer Vaccines Market is widespread vaccine hesitancy and low levels of public awareness regarding the benefits of cancer-preventive vaccines. Misinformation, cultural misconceptions, and distrust in healthcare institutions have contributed to suboptimal vaccine uptake in several countries.

In Nigeria, a 2022 study published by the Nigerian Medical Association found that only 35% of mothers were aware of the link between HPV and cervical cancer, underscoring a significant knowledge gap that affects vaccination decisions. Moreover, religious and traditional beliefs in some communities have discouraged vaccine acceptance, especially for adolescent-targeted vaccines. In the Middle East, Saudi Arabia and Kuwait have faced similar issues, where misinformation spread via social media platforms has fueled doubts about vaccine efficacy. These barriers remain persistent obstacles to achieving widespread cancer vaccine coverage in the region.

MARKET OPPORTUNITIES

Expansion of Private Sector Engagement in Vaccine Development and Distribution

An emerging opportunity in the MEA Cancer Vaccines Market is the increasing involvement of private sector players in vaccine development, manufacturing, and distribution. Over the past few years, multinational pharmaceutical companies and local biotech firms have expanded their presence in the region, aiming to bridge the gap between global innovation and local accessibility.

Companies such as GlaxoSmithKline (GSK), Merck & Co., and Sanofi Pasteur have strengthened their commercial operations in key markets like Egypt, South Africa, and the UAE, leveraging strategic partnerships with local distributors to enhance vaccine availability. In addition, domestic biotechnology firms are gaining traction, with South Africa’s Biovac and Egypt’s VACSERA playing pivotal roles in developing affordable HPV vaccine alternatives. The South African Health Products Regulatory Authority (SAHPRA) reported that local production of HPV vaccines reduced import dependency in 2023 , lowering costs and improving supply stability. Furthermore, the rise of telemedicine and digital health platforms is facilitating better patient education and vaccine tracking, thereby improving adherence to multi-dose regimens.

Integration of Digital Health Technologies in Immunization Campaigns

The integration of digital health technologies into immunization campaigns represents a transformative opportunity for the MEA Cancer Vaccines Market. With increasing mobile phone penetration and internet connectivity, governments and health agencies are adopting digital tools to streamline vaccine delivery, monitor coverage, and enhance public engagement.

In Rwanda, the Ministry of Health implemented a national digital immunization registry in 2022, allowing real-time monitoring of HPV vaccine administration across all age groups, which resulted in an increase in completion rates within the first year. Beyond administrative benefits, digital platforms are being used to counter misinformation and promote vaccine awareness. Social media campaigns coordinated by WHO and local health ministries in Nigeria and Egypt have reached millions of users, effectively countering vaccine hesitancy with evidence-based content.

MARKET CHALLENGES

Economic Instability and Budgetary Constraints in Public Health Spending

Economic volatility across several MEA countries poses a significant challenge to sustained investment in cancer vaccination programs. Many governments in the region face fluctuating exchange rates, inflationary pressures, and constrained fiscal budgets, limiting their capacity to procure and distribute vaccines consistently.

In countries like Nigeria and Egypt, rising inflation has eroded purchasing power and strained public health expenditures. Similarly, in South Africa, budget constraints have delayed the expansion of HPV vaccination programs beyond schoolgirls to include boys and adult women.

Apart from these, reliance on external funding mechanisms, such as Gavi and the Global Fund, introduces uncertainty in long-term planning. As per the Center for Strategic and International Studies (CSIS), fluctuations in donor contributions have led to supply disruptions in several middle-income countries that no longer qualify for full subsidies. These financial constraints make it challenging to maintain consistent vaccine coverage, especially for multi-dose regimens like HPV, which require sustained investment over time.

Regulatory and Approval Delays for New Cancer Vaccines

Regulatory inefficiencies and prolonged approval timelines for new cancer vaccines represent a formidable challenge for the MEA Cancer Vaccines Market. Unlike developed markets where regulatory frameworks are streamlined and expedited, many MEA countries experience bureaucratic delays in evaluating and approving novel vaccine formulations.

In South Africa, the South African Health Products Regulatory Authority (SAHPRA) has faced criticism for its lengthy review process, causing delays in the introduction of next-generation HPV vaccines with broader strain coverage. Similarly, in Egypt, the Egyptian Drug Authority (EDA) has encountered bottlenecks in coordinating clinical trial data assessments, slowing down market entry for innovative cancer immunotherapies. Without standardized approval pathways and accelerated regulatory mechanisms, the MEA Cancer Vaccines Market will continue to lag behind global peers in adopting cutting-edge immunization solutions.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Cancer Type Insights

The cervical cancer represented the largest segment, accounting for 41.4% of total market share in 2025. This dominance is primarily attributed to the high incidence of cervical cancer across Sub-Saharan Africa and parts of North Africa, where it remains the leading cause of female cancer mortality. According to the International Agency for Research on Cancer (IARC), over 75,000 new cases of cervical cancer were reported annually in Africa between 2020 and 2023 , with limited access to early diagnosis and treatment contributing to high fatality rates. The World Health Organization (WHO) has emphasized that vaccination against Human Papillomavirus (HPV), the primary causative agent of cervical cancer, remains one of the most cost-effective prevention strategies. Additionally, recent policy changes in Egypt and Morocco have expanded HPV vaccination coverage to include adolescent boys, further reinforcing the growth of this segment.

The fastest-growing segment in the MEA Cancer Vaccines Market by cancer type is prostate cancer, projected to grow at a CAGR of 12.4% during the forecast period. This rapid growth is driven by increasing awareness about prostate cancer risk factors and the emergence of novel therapeutic vaccines targeting advanced stages of the disease. According to the study, prostate cancer incidence has risen in urban centers across Nigeria, South Africa, and Kenya since 2018 , making it one of the most prevalent cancers among men in the region. In response, governments and research institutions have begun investing in clinical trials and pilot immunotherapy programs. For example, the University of Cape Town launched a phase I trial in 2023 for a dendritic cell-based prostate cancer vaccine aimed at improving survival outcomes. Additionally, multinational pharmaceutical companies such as Merck & Co. and AstraZeneca are expanding their oncology portfolios into MEA markets, introducing personalized cancer vaccines tailored to genetic profiles common in African populations. With growing scientific evidence supporting its efficacy and rising healthcare expenditure in key Gulf Cooperation Council (GCC) nations, the prostate cancer vaccines segment is poised for accelerated expansion in the coming years.

By Vaccine Type Insights

The largest segment in the MEA Cancer Vaccines Market by vaccine type is protein-based vaccines, which accounted for a 37.7% of the total market in 2025. This segment's dominance is due to the widespread use of recombinant protein vaccines such as the HPV and Hepatitis B vaccines, which have been integrated into national immunization programs across several African and Middle Eastern countries.

Countries like Kenya, Ethiopia, and the United Arab Emirates have led procurement efforts, supported by the Gavi-funded HPV vaccine initiative.

These vaccines benefit from established manufacturing processes, regulatory approvals, and proven safety profiles, making them the preferred choice for large-scale immunization initiatives. As governments continue to prioritize preventive oncology through vaccination, protein-based vaccines remain central to the region’s cancer control strategy.

The fastest-growing segment in the MEA Cancer Vaccines Market by vaccine type is genetic vaccines, anticipated to grow at a CAGR of 14.1%. This surge is largely driven by advancements in mRNA and DNA vaccine technologies, particularly following the success of genetic platforms during the COVID-19 pandemic.

Clinical trials for therapeutic cancer vaccines based on mRNA platforms are underway in South Africa and the UAE, focusing on personalized treatments for melanoma, prostate cancer, and cervical cancer.

Similarly, the University of Witwatersrand in South Africa announced collaborations with European biotech firms to develop localized mRNA vaccine production capabilities. As research progresses and regulatory frameworks adapt, genetic vaccines are positioned to transform the landscape of cancer immunotherapy in the MEA region.

COUNTRY LEVEL ANALYSIS

South Africa held the leading position in the MEA Cancer Vaccines Market, accounting for 23.1% of the regional market share in 2025. South Africa’s prominence is driven by its relatively advanced healthcare infrastructure, active participation in global health initiatives, and strong government commitment to HPV and Hepatitis B vaccination programs.

Also, the University of Cape Town reported that clinical trials for therapeutic cancer vaccines, including those targeting cervical and prostate cancers, had gained significant traction, attracting both domestic and international funding. South Africa also benefits from a well-established regulatory framework under the South African Health Products Regulatory Authority (SAHPRA), which supports faster approval of innovative vaccines. With ongoing investments in biotechnology and digital health systems, South Africa continues to serve as a model for cancer vaccine adoption in the broader MEA region.

United Arab Emirates (UAE) has strategic focus on preventive healthcare and early adoption of advanced medical technologies have positioned it as a key player in the sector.

Additionally, the UAE has been actively involved in regional collaboration through the World Health Organization (WHO) and the Islamic Development Bank, promoting vaccine equity across GCC nations. Recent investments in genomic medicine and personalized cancer vaccines have further strengthened the UAE’s position in the market. With continuous support from federal health policies and growing interest in genetic and therapeutic vaccines, the UAE remains a major contributor to cancer vaccine innovation and distribution in the MEA region.

Egypt’s market standing is bolstered by its large population base, increasing cancer burden, and expanding government-led immunization initiatives. As per the National Cancer Institute of Egypt, a notable decline in precancerous cervical lesions among vaccinated cohorts, reinforcing the effectiveness of preventive vaccination. Egypt has also made strides in Hepatitis B immunization, achieving high infant vaccination rates. Moreover, the country’s state-owned vaccine manufacturer, VACSERA, plays a pivotal role in supplying affordable hepatitis B and HPV vaccines domestically and across African markets. With continued government backing and donor-supported programs through Gavi and UNICEF, Egypt maintains a strong policy framework for vaccine deployment, positioning it as a key market participant in the MEA region.

Saudi Arabia’s prowess in healthcare modernization and high vaccination coverage make it a standout performer in the Middle East. According to the Saudi Ministry of Health, the country implemented a school-based HPV vaccination program in 2021 , targeting girls aged 11–14, which resulted in over 85% uptake within two years . Additionally, Saudi Arabia has been actively involved in regional collaboration through the Gulf Cooperation Council (GCC), aligning regulatory standards and procurement strategies for vaccine access. The country’s Vision 2030 initiative includes a strong emphasis on preventive medicine and digital health integration, facilitating real-time tracking of immunization data. As a result, Saudi Arabia serves as a model for efficient cancer vaccine rollout and policy-driven healthcare reform in the MEA region.

Rest of MEA (RoMEA) , comprising countries such as Kenya, Ethiopia, Nigeria, Sudan, Morocco, and other African and Middle Eastern nations , collectively accounts for a notable share of the MEA Cancer Vaccines Market in 2025 . While individually these markets may be smaller, together they represent significant potential for future growth. According to the World Health Organization (WHO), HPV vaccine coverage in RoMEA averaged 45% in 2023 , with notable variations between urban and rural areas. Ethiopia has made progress through mobile vaccination units, increasing rural accessibility, as highlighted by the Ethiopian Public Health Institute. Meanwhile, West African countries like Nigeria and Ghana have benefited from donor-supported programs through Gavi and UNICEF, enabling large-scale vaccine procurement. With improving healthcare policies, increasing foreign aid, and expanding vaccine manufacturing partnerships, RoMEA presents emerging opportunities for market expansion in the coming decade.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Companies playing an influential role in the Middle East and Africa cancer vaccines market are Dendreon, GlaxoSmithKline, and Merck. In addition, companies with their products in the pipeline are Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies, Bavarian Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest Biotherapeutics, NovaRx, OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech.

The MEA Cancer Vaccines Market is characterized by a competitive landscape shaped by both multinational pharmaceutical companies and emerging regional players. Major global firms such as Merck & Co., GlaxoSmithKline (GSK), and Sanofi Pasteur dominate due to their established product portfolios, extensive distribution networks, and longstanding relationships with public health institutions. Their presence is further reinforced through participation in WHO- and Gavi-led procurement frameworks that streamline vaccine acquisition for MEA governments. However, increasing investments in biotechnology and vaccine manufacturing within countries like South Africa, Egypt, and Saudi Arabia are enabling domestic firms to gain traction. These regional players offer cost-effective alternatives and benefit from government-backed initiatives aimed at reducing import dependency. Additionally, growing collaboration between private sector entities and academic institutions is fostering innovation in next-generation cancer vaccines, including therapeutic and genetic platforms. Despite this progress, challenges such as regulatory delays, fragmented healthcare systems, and budgetary constraints continue to shape the competitive dynamics of the market, requiring sustained strategic adaptation from all participants.

Top Players in the Market

One of the leading players in the MEA Cancer Vaccines Market is Merck & Co. , known for its globally recognized HPV vaccine, Gardasil. The company has been instrumental in expanding access to cervical cancer prevention across Africa and the Middle East through strategic partnerships with governments and global health organizations. Merck’s initiatives include donation programs, technology transfer agreements, and awareness campaigns aimed at improving vaccine coverage in low-resource settings.

Another key player is GlaxoSmithKline (GSK) , which offers Cervarix, a widely used HPV vaccine that has contributed significantly to national immunization programs in several MEA countries. GSK has focused on strengthening regional supply chains and collaborating with public health authorities to enhance vaccine affordability and distribution efficiency. Its long-standing engagement in vaccine development and delivery makes it a vital contributor to cancer prevention efforts in the region.

The third major participant is Sanofi Pasteur , a global leader in vaccine production with a strong presence in the MEA market. The company supports immunization programs by supplying Hepatitis B vaccines, which play a crucial role in liver cancer prevention. Sanofi Pasteur also engages in capacity-building initiatives and participates in international procurement mechanisms, ensuring timely availability of life-saving vaccines across diverse populations in the MEA region.

Top Strategies Used by Key Market Participants

Key players in the MEA Cancer Vaccines Market have adopted several strategies to strengthen their positions. One major approach is collaborating with international health organizations and local governments to align with national immunization goals and secure long-term vaccine supply contracts. These collaborations facilitate broader market access and help manufacturers meet public health objectives in resource-limited settings.

Another important strategy is investing in local manufacturing capabilities and regional distribution networks through partnerships with domestic biotech firms. This not only enhances supply chain efficiency but also reduces logistical barriers, especially in remote areas where infrastructure limitations are significant.

Lastly, companies are increasingly focusing on launching community-based education and awareness campaigns to combat vaccine hesitancy. By engaging with healthcare professionals, schools, and religious leaders, these firms aim to build trust and improve acceptance of preventive cancer vaccines among target populations across the MEA region.

RECENT HAPPENINGS IN THE MARKET

In January 2025, Merck & Co. expanded its partnership with the African Union to support HPV vaccine rollouts across Sub-Saharan Africa, aiming to increase accessibility and coverage among adolescent girls through targeted immunization drives.

In May 2023, GlaxoSmithKline launched an educational initiative in collaboration with the Egyptian Ministry of Health to raise awareness about the importance of HPV vaccination and address misconceptions among parents and caregivers.

In October 2023, Sanofi Pasteur signed a multi-year agreement with the Saudi Arabian government to supply Hepatitis B vaccines under the national immunization program, reinforcing its role in liver cancer prevention efforts in the Gulf region.

In March 2025, VACSERA, Egypt’s state-owned vaccine manufacturer, announced a joint research project with a European biotech firm to develop a locally produced HPV vaccine tailored for the African population, enhancing regional self-sufficiency.

In August 2023, AstraZeneca entered into a strategic alliance with the University of Cape Town to advance clinical trials for a novel dendritic cell-based prostate cancer vaccine, marking a step toward personalized oncology solutions in South Africa.

MARKET SEGMENTATION

This research report on the mea cancer vaccines market has been segmented and sub-segmented into the following categories

By Cancer Type

• cervical cancer
• fastest-growing

By Vaccine Type

• largest
• fastest-growing

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA